



Supplementary Table S1. Comparison of baseline biomarkers between ASD patients who developed severe adverse events during follow-up and those who did not in the entire population.

Biomarkers	SAE−	SAE+	<i>p</i> Value
WBC (10 ³ /uL)	5.1 ± 1.7	4.9 ± 1.7	0.56
Hb (g/dL)	12.4 ± 1.2	12.3 ± 1.3	0.84
PLT (10 ³ /uL)	24.1 ± 7.1	24.2 ± 9.6	0.94
TLC (10 ² /uL)	30.3 ± 9.0	30.9 ± 8.2	0.79
TP (g/dL)	6.7 ± 0.5	6.7 ± 0.6	0.90
ALB (g/dL)	4.0 ± 0.3	3.9 ± 0.5	0.22
BUN (mg/dL)	15.1 ± 4.2	16.4 ± 4.7	0.11
Cr (mg/dL)	0.67 ± 0.1	0.78 ± 0.23	0.01 *
CRP (mg/dL)	0.23 ± 1.25	0.06 ± 0.07	0.44
AST(IU/L)	22.3 ± 11.3	22.6 ± 4.6	0.85
ALT(IU/L)	16.2 ± 7.1	16.7 ± 6.0	0.66
PT-INR (%)	1.0 ± 0.1	0.9 ± 0.0	0.54
aPTT (sec.)	28.3 ± 3.4	27.0 ± 3.1	0.13

Means and standard deviations; * indicates statistically significant. TLC: Total lymphocyte count.